Format

Send to

Choose Destination
Curr Opin Pharmacol. 2018 Dec;43:111-117. doi: 10.1016/j.coph.2018.08.015. Epub 2018 Sep 21.

New developments in the treatment of gastroparesis and functional dyspepsia.

Author information

1
TARGID, University Hospital, Leuven, Belgium. Electronic address: jan.tack@kuleuven.be.
2
Mayo Clinic, Rochester, MN, USA.

Abstract

Functional dyspepsia (FD) and gastroparesis are frequent causes of upper gastrointestinal symptoms such as postprandial fullness, early satiation, epigastric pain or burning, upper abdominal bloating, bothersome belching, nausea and vomiting. The underlying pathophysiological mechanisms are heterogeneous and involved mechanisms such as abnormal gastric motility (accommodation, emptying), visceral hypersensitivity, low grade mucosal inflammation and cellular changes in enteric nerves, muscle or interstitial cells of Cajal. Patient-reported outcomes for evaluating treatment efficacy in these conditions were recently developed and validated. Prokinetic agents, which enhance gastric motility, are used for treating both gastroparesis and FD. In FD, besides acid suppressive therapy and Helicobacter pylori eradication, neuromodulators and drugs that enhance gastric accommodation can be applied. In gastroparesis, anti-emetics may also provide symptom relief. Novel approaches under evaluation in these conditions are the fundus relaxing agents acotiamide and buspirone and the antidepressant mirtazapine in FD. For gastroparesis, recently studied agents include the prokinetic ghrelin agonist relamorelin, the prokinetic serotonergic agents velusetrag and prucalopride, the anti-emetic aprepitant and per-endoscopic pyloric myotomy procedures.

PMID:
30245474
DOI:
10.1016/j.coph.2018.08.015

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center